BioMarin Pharmaceutical (BMRN)
(Delayed Data from NSDQ)
$66.60 USD
+0.71 (1.08%)
Updated Nov 1, 2024 04:00 PM ET
After-Market: $66.63 +0.03 (0.05%) 7:58 PM ET
2-Buy of 5 2
B Value A Growth A Momentum A VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$66.60 USD
+0.71 (1.08%)
Updated Nov 1, 2024 04:00 PM ET
After-Market: $66.63 +0.03 (0.05%) 7:58 PM ET
2-Buy of 5 2
B Value A Growth A Momentum A VGM
Zacks News
Centene (CNC) Chosen to Serve New Hampshire's Medicaid Members
by Zacks Equity Research
Centene's (CNC) subsidiary has been selected by the DHHS to serve the diversified health needs of members of New Hampshire's Medicaid program and thereby, earn more members.
Zacks.com featured highlights Otter Tail, OraSure, BioMarin and Regeneron
by Zacks Equity Research
Otter Tail, OraSure, BioMarin and Regeneron have been highlighted in this Screen of The Week article.
Buy These 4 Low-Beta Stocks to Counter Market Volatility
by Nilanjan Banerjee
It is imperative to build a portfolio of low-beta stocks to sail through a volatile market. Otter Tail (OTTR), Regeneron (REGN), OraSure (OSUR) and BioMarin Pharmaceutical (BMRN) are well-poised to gain.
BioMarin Pharmaceutical (BMRN) is a Top-Ranked Growth Stock: Should You Buy?
by Zacks Equity Research
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Pfizer's (PFE) Hemophilia Candidate BLA Gets FDA Acceptance
by Zacks Equity Research
The FDA decision on Pfizer's (PFE) BLA for marstacimab for hemophilia A and B is expected in the fourth quarter of 2024, while the European Commission's decision is expected in 2025.
Why Is Denali Therapeutics Inc. (DNLI) Down 5.2% Since Last Earnings Report?
by Zacks Equity Research
Denali Therapeutics Inc. (DNLI) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Why Is BioMarin (BMRN) Up 14.3% Since Last Earnings Report?
by Zacks Equity Research
BioMarin (BMRN) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
BioMarin (BMRN) Q3 Earnings in Line, Sales Miss, '23 View Cut
by Zacks Equity Research
BioMarin's (BMRN) Q3 earnings are in line with estimates but miss the mark on sales. The company lowered its 2023 guidance due to global pricing and reimbursement delays for Roctavian.
BioMarin (BMRN) Q3 Earnings: Taking a Look at Key Metrics Versus Estimates
by Zacks Equity Research
While the top- and bottom-line numbers for BioMarin (BMRN) give a sense of how the business performed in the quarter ended September 2023, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
Harmony Biosciences Holdings, Inc. (HRMY) Lags Q3 Earnings Estimates
by Zacks Equity Research
Harmony Biosciences Holdings, Inc. (HRMY) delivered earnings and revenue surprises of -5.97% and 11.39%, respectively, for the quarter ended September 2023. Do the numbers hold clues to what lies ahead for the stock?
The Zacks Analyst Blog Highlights Bristol Myers, PTC Therapeutics, Beam Therapeutics and BioMarin Pharmaceutical
by Zacks Equity Research
Bristol Myers, PTC Therapeutics, Beam Therapeutics and BioMarin Pharmaceutical are included in this Analyst Blog.
Biotech Stock Roundup: BMY's Q3 Results, PTCT Up on Deal, BEAM's Restructuring News
by Zacks Equity Research
Earnings and other updates from Bristol Myers (BMY) and PTC Therapeutic (PTCT) are in focus in the biotech sector.
Merus N.V. (MRUS) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
by Zacks Equity Research
Merus N.V. (MRUS) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
BioMarin Pharmaceutical (BMRN) Reports Next Week: Wall Street Expects Earnings Growth
by Zacks Equity Research
BioMarin (BMRN) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Will the Medicare Unit Aid Molina Healthcare's (MOH) Q3 Earnings?
by Zacks Equity Research
Molina Healthcare's (MOH) Q3 results are expected to benefit on growing premiums and an expanding customer base within its Medicaid and Medicare businesses, partly offset by increased medical costs.
Elevance Health (ELV) Q3 Earnings Beat on Carelon Unit Strength
by Zacks Equity Research
Membership growth in the Medicare Advantage business and strong segmental performance aid Elevance Health's (ELV) Q3 results. An encouraging 2023 earnings guidance also bodes well for investors.
Why BioMarin (BMRN) Could Beat Earnings Estimates Again
by Zacks Equity Research
BioMarin (BMRN) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
CHMP Endorses BioMarin's (BMRN) Voxzogo for Use in Infants
by Zacks Equity Research
A final decision study on BioMarin's (BMRN) Voxzogo to treat children above four months with achondroplasia is expected before year's end.
Why Is Seattle Genetics (SGEN) Up 6.5% Since Last Earnings Report?
by Zacks Equity Research
Seattle Genetics (SGEN) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Why Is Incyte (INCY) Down 0.7% Since Last Earnings Report?
by Zacks Equity Research
Incyte (INCY) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
BioMarin (BMRN) Q2 Earnings & Sales Top, Voxzogo Drives Sales
by Zacks Equity Research
BioMarin (BMRN) beats on earnings and sales estimates in the second quarter on the back of robust demand for Voxzogo.
BioMarin (BMRN) Q2 Earnings: Taking a Look at Key Metrics Versus Estimates
by Zacks Equity Research
Although the revenue and EPS for BioMarin (BMRN) give a sense of how its business performed in the quarter ended June 2023, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
BioMarin Pharmaceutical (BMRN) Tops Q2 Earnings and Revenue Estimates
by Zacks Equity Research
BioMarin (BMRN) delivered earnings and revenue surprises of 14.89% and 0.65%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?
Biotech Stock Roundup: BMRN's Gene Therapy Gets Approval, SGTX Up on Buyout by LLY
by Zacks Equity Research
Regulatory and acquisition updates from BioMarin (BMRN) and Sigilon (SGTX) are in focus in the biotech sector.
BioMarin (BMRN) Gets FDA Nod for Hemophilia A Gene Therapy
by Zacks Equity Research
Following FDA's approval, BioMarin's (BMRN) Roctavian becomes the first gene therapy for treating severe hemophilia A.